Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In 1989, Sir David Weatherall founded the Institute of Molecular Medicine to bridge the gap between basic science and clinical medicine. To mark 35 years since the MRC WIMM opened its labs, we're looking back on some of our highlights and achievements.

We spoke with many of our current and former scientists, who shared details from their time here and some of the Institute's lasting contributions to science.

Reflecting on her time at the Institute, Dame Kay Davies said:

It was very supportive, everyone was highly competitive but very friendly. It was just a great community of people.

Some of the highlights mentioned in the video include Professor Angela Vincent's work on the role of the immune system in neurological diseases, the development of prenatal diagnosis for genetic diseases (particularly thalassemia and sickle cell disease) and Sir Peter Ratcliffe's Nobel Prize-winning research on oxygen sensing.

 

The WIMM started me off and it's starting that's the most important thing in science.

- Professor Sir Peter Ratcliffe, Nobel Prize Laureate (2019, Physiology or Medicine)

 

Learn more from our interactive timeline:

Accessible version of the MRC WIMM interactive timeline.

Similar stories

Professor KJ Patel awarded Royal Society Buchanan Medal

Congratulations to Professor Patel, who has received the Buchanan Medal, which recognises distinguished contributions to the biomedical sciences.

New pump-priming awards support cross-cutting research across RDM

Five Radcliffe Department of Medicine research teams have secured pump-priming funding to support new collaborations and early-stage research aligned with RDM’s cross-cutting research themes.

First real-world trial shows AI could reduce need for contrast injections in heart MRI scans

The technology could make advanced heart MRI faster, cheaper and more accessible.

Beyond cancer dependency maps: the PRECISE vision

Dr Sumana Sharma is one of the founding partners of a major new pan-European initiative that aims to transform how scientists identify and target cancer's weaknesses, moving beyond simply mapping cancer vulnerabilities towards predicting them before they are experimentally tested.

MRC WIMM achieves Gold Green Impact award

Congratulations to the Institute's Green Impact team, who achieved Gold in the University of Oxford's 2026 Green Impact awards.

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Similar stories

Professor KJ Patel awarded Royal Society Buchanan Medal

Congratulations to Professor Patel, who has received the Buchanan Medal, which recognises distinguished contributions to the biomedical sciences.

New pump-priming awards support cross-cutting research across RDM

Five Radcliffe Department of Medicine research teams have secured pump-priming funding to support new collaborations and early-stage research aligned with RDM’s cross-cutting research themes.

First real-world trial shows AI could reduce need for contrast injections in heart MRI scans

The technology could make advanced heart MRI faster, cheaper and more accessible.

Beyond cancer dependency maps: the PRECISE vision

Dr Sumana Sharma is one of the founding partners of a major new pan-European initiative that aims to transform how scientists identify and target cancer's weaknesses, moving beyond simply mapping cancer vulnerabilities towards predicting them before they are experimentally tested.

MRC WIMM achieves Gold Green Impact award

Congratulations to the Institute's Green Impact team, who achieved Gold in the University of Oxford's 2026 Green Impact awards.

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.